In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species

Chemotherapy

Volumn 46, Issue 4, 2000, Pages 253-266

  Marchese, Anna ^b   Salerno, Angelo ^b   Pesce, Adelaide ^b   Debbia, Eugenio A ^a   Schito, Gian Carlo ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b NONE

Author keywords

Clostridium difficile; Rifaximin; Spontaneous resistance

Indexed keywords

METRONIDAZOLE; NEOMYCIN; RIFAXIMIN; VANCOMYCIN;

AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM MUTANT; CLOSTRIDIUM DIFFICILE; DRUG EFFECT; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0033932776     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007297     Document Type: Article

References (30)

1. Levine MM: Escherichia coli that cause diarrhea: Enterotoxigenic, enteropathogenic, enteroin vasive, enterohemorrhagic, and enteroadherent. J Infect Dis 1987;155:377-389.
2. Vince AJ, Burridge SM: Ammonia production by intestinal bacteria: The effects of lactose, lactulose and glucose. J Med Microbiol 1980;13: 177-181.
3. Fekety R: Antibiotic-associated colitis; in Mandell GL, Bennet JE, Dlin R (eds): Principles and Practice of Infectious Diseases, cd 4. New York, Churchill Livingstone, 1995. pp 978-987.
4. Crossley IR, Williams R: Progress in the treatment of chronic portasystemic encephalopathy, Gut 1984:25: 85-98.
5. McGowan KL. Kader HA: Clostridium difficile infection in children. Clin Microbiol Lett 1999;21:49-53.
6. Zieve L: The mechanism of hepatic coma. Hepatology 1981;1:360-365.
7. Crossley IR, Wardle EN, Williams R: Biochemical mechanisms of hepatic encephalopathy. Clin Sci (Colch) 1983;64:247-252.
8. Kaplan AH, Gilligan PH, Faclam RR: Recovery of resistant enterococci during vancomycin prophylaxis. J Clin Microbiol 1988;26: 1216-1218.
9. Landman D, Quale JM: Management of infections due to resistant enterococci: A review of therapeutic options. J Antimicrob Chemother 1997;40:161-170.
10. Levy SB: Multidrug resistance - a sign of the times. N Engl J Med 1998;338:1376-1378.
11. Venturini AP, Marchi E: In vitro and in vivo evaluation of L/105, a new topical intestinal rifamycin. Chemioterapia 1986;5:257-262.
12. Palermo G, Di Gregono P, Coffa G: Effectiveness of the L/105 compound in the treatment of acute diarrhoeal diseases. A short-term controlled study. Med Prax 1984;5: 147-152.
13. Alvisi V, D'Ambrosi A, Loponte A, Pazzi P, Greco A, Zangirolami A. Palazzini E: Rifaximin, a rifamycin derivative for use in the treatment of intestinal bacterial infections in seriously disabled patients. J Int Med Res 1987;15:49-56.
14. Stornello C, Salanitri G: Controlled trial on the clinical effectiveness of the new antidiarrhoeal drug rifaximin. Med Prax 1987;8:69-78.
15. Gillis JC, Brogden RN: Rifaximin: A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995;49:467-484.
16. Hoover WW, Gerlach EH, Hoban DJ, Eliopoulos GM, Pfaller MA, Jones RN: Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis 1993;16:111-118.
17. Luttichau U, Arcangeli P, Sinapi S: The use of Rifaximin in the treatment of acute diarrhoeal enteritis: Open study. Panminerva Med 1985: 27:129-132.
18. Testa R, Eftimiadi C, Sukkar GS, De Leo C, Rovida S, Schito GC, Celle G: A non-absorbable rifamicin for treatment of hepatic encephalopathy. Drugs Exp Clin Res 1985;11: 387-392.
19. Eftimiadi C, De Leo C, Schito GC: Treatment of hepatic encephalopathy with L/105, a new non-absorbable rifamycin. Drugs Exp Clin Res 1984;10:691-696.
20. De Leo C, Eftimiadi C, Schito GC: Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 1986; 12:979-981.
21. Descombe JJ, Dubourg D, Picard M, Palazzini E: Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994;14:51-56.
22. Marchi E, Montecchi L, Venturini AP, Mascellani G, Brufani M, Cellai L: 4-Deoxypyrido[1′,2′1,2]imidazo[5,4-c]rifamycin SV derivatives. A new series of semisynthetic rifamycins with high antibacterial activity and low gastroenteric absorption. J Med Chem 1985;28:960-963.
23. Venturini AP: Pharmacokinetics of L/105, a new rifamycin, in rats and dogs, after oral administration. Chemotherapy 1983;29:1-3.
24. 3H-rifaximin to rats. Chemioterapia 1984;3:373-377.
25. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically (1997), ed 4; Approved standard M7-A4. Wayne, PA, NCCLS, 1997.
26. National Committee for Clinical Laboratory Standards: Methods for antimicrobial susceptibility testing of anaerobic bacteria (1995), ed 3; Approved Standard M11-A3. Wayne, PA, NCCLS, 1997.
27. Marchese A, Debbia EA, Schito GC: In vitro activity of quinupristin/dalfopristin against selected bacterial pathogens isolated in Italy. Clin Microbiol Infect 1999;5:488-495.
28. Marchese A, Debbia EA, Bacca D, Balistreri G, Musolino B, Schito GC: Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns. Drugs 1997:54(suppl 6):11-20.
29. Debbia EA, Pesce A, Chiesa M, Ricotta N, Schito GC: Microbiologic profile of ceftibuten, a new oral cephalosporin. Drugs Exp Clin Res 1992;18:129-139.
30. Gemmel GC, Lorian V: Effects of low concentrations of antibiotics on bacterial ultrastructure, virulence, and susceptibility to immunodefenses: Clinical significance; in Lorian V (ed): Antibiotics in Laboratory Medicine, ed 4. Baltimore, Williams and Wilkins, 1996, pp 397-452.